Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Current Deferred Revenue (2022 - 2024)

Praxis Precision Medicines (PRAX) has 3 years of Current Deferred Revenue data on record, last reported at $1.2 million in Q3 2024.

  • For Q3 2024, Current Deferred Revenue fell 24.61% year-over-year to $1.2 million; the TTM value through Sep 2024 reached $1.2 million, down 24.61%, while the annual FY2023 figure was $1.4 million, 72.16% down from the prior year.
  • Current Deferred Revenue reached $1.2 million in Q3 2024 per PRAX's latest filing, down from $1.2 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $5.0 million in Q4 2022 and bottomed at $1.2 million in Q3 2024.
  • Average Current Deferred Revenue over 3 years is $2.0 million, with a median of $1.5 million recorded in 2023.
  • Peak YoY movement for Current Deferred Revenue: tumbled 72.16% in 2023, then fell 24.61% in 2024.
  • A 3-year view of Current Deferred Revenue shows it stood at $5.0 million in 2022, then crashed by 72.16% to $1.4 million in 2023, then fell by 15.95% to $1.2 million in 2024.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $1.2 million in Q3 2024, $1.2 million in Q2 2024, and $1.3 million in Q1 2024.